1. Age ≥ 18 years
2. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
3. Histologically confirmed diagnosis of any of the following:
• Gastric or gastroesophageal junction adenocarcinoma
• Esophageal adenocarcinoma
• Colorectal adenocarcinoma (CRC)
- Hepatocellular carcinoma (HCC)
4. Patients should have advanced (stage 4) or locally unresectable (stage III) disease.
5. Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.1
6. Patients must consent to undergo a required screening/baseline biopsy procedure (and
potentially another tumor biopsy at time of disease response and progression) for
7. Patients with gastric, gastroesophageal, or esophageal adenocarcinoma must show
evidence of progression or intolerance to at least two previous standard of care
8. Patients with CRC must show evidence of progression or intolerance to at least 2
previous standard of care systemic therapy. Ras wild type patients should fail
epidermal growth factor receptor (EGFR) monoclonal antibody (panitumumab or cetuximab)
to be eligible.
9. Patients with HCC must must be treatment naive or show evidence of disease progression
or intolerance to at least 1 previous standard of care systemic therapy.
10. Adequate organ and marrow function.
11. Evidence of post-menopausal status or negative urinary or serum pregnancy test for
female pre-menopausal patients.
12. Women of child-bearing potential and men with partners of child-bearing potential must
agree to use the highly effective forms of contraception prior to study entry, for the
duration of study participation, and for 180 Days post completion of therapy. Men of
child-bearing potential must not donate sperm while on this study and for 180 Days
after their last study treatment.
1. Prior randomization or treatment in a previous durvalumab and/or tremelimumab clinical
study regardless of treatment arm assignment (HCC patients fulfilling this criterion
2. Prior treatment with a Programmed cell death protein 1 (PD1) or (PD-L1) inhibitor,
including durvalumab, or anti PD-L2 (HCC patients with prior exposure to these agents
- Prior treatment with cabozantinib or other Receptor for hepatocyte growth factor
(MET) or Dual MET/ Hepatocyte growth factor (HGF) monoclonal antibodies or
MET/HGF tyrosine kinase inhibitors (TKIs), including crizotinib, foretinib,
tivantinib, rilotumumab, and onartuzumab.
3. Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess
within 6 months before first dose.
* Evidence of tumor invading the GI tract, (Defined as T4 primary tumor in patients
with gastric, gastroesophageal and esophageal adenocarcinoma and CRC).
4. Evidence of active peptic ulcer disease, inflammatory bowel disease (eg, Crohn's
disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis,
acute pancreatitis, acute obstruction of the pancreatic duct or common bile duct, or
gastric outlet obstruction.
5. Inability to swallow tablets.
6. Uncontrollable ascites or pleural effusion.
7. Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease
8. Clinically significant hematuria, hematemesis, or hemoptysis of >0.5 tsp (2.5ml) of
red blood, or other history of significant bleeding within 12 weeks.
* Any sign indicative of pulmonary hemorrhage within 3 months.
- Lesions invading any major blood vessels. HCC subjects with lesions invading the
hepatic portal vasculature are eligible.
9. Any unresolved toxicity CTCAE Grade ≥2 from previous anticancer therapy
10. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of
radiation within 4 weeks of the first dose of study drug
11. Major surgery (eg, Gastrointestinal (GI) surgery, removal or biopsy of brain
metastasis) within 8 weeks before first dose of study treatment.
12. Current or prior use of immunosuppressive medication within 14 days before the first
dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or
systemic corticosteroids at physiological doses.
13. History of allogenic organ transplantation.
14. Active or prior documented autoimmune or inflammatory disorders
15. History of active primary immunodeficiency
16. Active infection including tuberculosis, hepatitis B, hepatitis C, or human
immunodeficiency virus. HCC patients with hepatitis B or C infection are allowed per
protocol specific criteria.
17. Receipt of live attenuated vaccine within 30 days prior to the first dose.
18. Uncontrolled hypertension defined as sustained blood pressure (BP) > 150 millimeter of
mercury (mm Hg) systolic or > 100 mm Hg diastolic despite optimal antihypertensive
19. Stroke, including transient ischemic attack (TIA), myocardial infarction (MI), or
other ischemic event, or thromboembolic event (eg, deep venous thrombosis, pulmonary
embolism) within 6 months before first dose. Participants with a diagnosis of deep
venous thrombosis (DVT) within 6 months are allowed if stable, asymptomatic, and
treated with Low Molecular Weight Heparin (LMWH) for at least 2 weeks before first
20. Has untreated central nervous system (CNS) metastases and/or carcinomatous meningitis
21. Clinically significant disorders that would preclude safe study participation.
22. History of another primary malignancy except for:
- Malignancy treated with curative intent/ resection and with no known active
disease before the first dose of investigational product (IP) and of low
potential risk for recurrence.
- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
- Adequately treated carcinoma in situ without evidence of disease.
24. Concomitant anticoagulation with oral anticoagulants (e.g., warfarin, direct thrombin
and Factor Xa inhibitors) or platelet inhibitors (e.g., clopidogrel). Allowed
anticoagulants are the following:
1. Low-dose aspirin for cardioprotection (per local applicable guidelines) is permitted.
2. Low-dose (prophylactic) low molecular weight heparins (LMWH) are permitted.
3. Anticoagulation with therapeutic doses of LMWH is allowed in subjects with no known
brain metastases, clinically significant hemorrhage, or complications from a
thromboembolic event on the anticoagulation regimen (subjects with HCC must also have
a screening platelet count >100,000/μl), and who have been on a stable dose of LMWH
for at least 1 week before first dose.
25. Known allergy or hypersensitivity to any of the study drugs or any of the study